NEW YORK (GenomeWeb) – A clinical trial for acute myeloid leukemia that employs next-generation sequencing and precision medicine treatment may be groundbreaking because of the level of collaboration among partners, according to the Leukemia & Lymphoma Society, the trial sponsor.

The Beat AML Master Trial may also provide a framework for how future clinical trials seeking precision medicine outcomes are conducted, according to its lead investigators.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.